BACKGROUND: Posaconazole therapeutic drug monitoring (TDM) is recommended to promote effective antifungal prophylaxis, but its utility has yet to be optimized. Breakthrough invasive fungal infections have been reported with serum concentrations/L, but there is little evidence to determine the optimal serum concentration for efficacy or concentrations associated with toxicity. Challenges for effective monitoring are greater in settings without posaconazole TDM facilities because of the long turnaround time before receipt of results.
Introduction
Posaconazole is an extended spectrum azole used for the treatment of invasive fungal infections (IFIs). It is recommended as first-line prophylaxis during leukemia induction treatment, prolonged neutropenia, and graft-versus-host disease. [1] The understanding of the exposure-response relationship in posaconazole prophylaxis is improving; however, therapeutic drug monitoring (TDM) may be an important tool to maximize efficacy. [2] The risk for each patient is dynamic and depends on host factors, target organisms, associated interventions, and hospital setting. [3] Pharmacokinetic properties of posaconazole (poor water solubility necessitating ingestion with a high-fat meal; absorption at low intestinal pH requiring acidic meals) and potential drug interactions further complicate absorption, which is evident with the oral suspension. [4] Use of the newer once-daily tablet formulation results in more consistent serum concentrations than the three times daily oral suspension. [5] The Australian guidelines recommend posaconazole concentrations ≥700 µg/L during prophylaxis. [6] Lower concentrations (between 500 and 700 µg/L) have been associated with breakthrough invasive fungal infections (IFIs). [7] However, the optimal posaconazole concentration during prophylaxis is not defined, [8] which makes real-time data to monitor concentrations crucial. [9] For patients managed within a reference center (i.e., metropolitan hospitals with posaconazole TDM facilities on-site), TDM can guide timely and appropriate drug dosage modifications. Previous clinical TDM studies have been conducted in such reference centers. [10] [11] [12] Those studies have shown that dose modification has resulted in more appropriate levels. Outside those settings, practical limitations on clinician access to results and time lag until dose adjustment risk reducing the utility of the process. [13] Very limited data exist on the value of posaconazole TDM in regional hospitals without posaconazole TDM facilities. [14] The aim of the study was the to evaluate the utility of posaconazole TDM for prophylaxis in a regional hospital without on-site TDM facilities. Posaconazole concentrations were performed in the setting of standard patient care, therefore Ethics Approval was not necessary.
Materials and Methods

This
Results
Thirty-eight posaconazole TDM episodes were performed on 18 hematology inpatients (Table 1) There was no difference in the proportion of concentrations between the oral suspension (31 concentrations, 16 below threshold) and the tablet (7 concentrations, 4 below threshold).
Discussion
Despite the recommendation of utilizing TDM for patients receiving prophylactic posaconazole, [6, 15] our study has identified barriers to appropriate TDM in a regional hospital without posaconazole TDM facilities. These include challenges in results retrieval, long turnaround time, and the variable interpretation of optimal serum concentrations.
The Australian guidelines recommend posaconazole oral suspension dosing of 200 mg three times daily; [1] half of the TDM episodes performed on this dose yielded concentrations <700 µg/L.
Only 21% of doses were changed in response to the low concentrations. None of these patients' followup concentrations were >700 µg/L, and none of them had further follow-up despite persistent low levels. With posaconazole therapy having high intra-patient and inter-patient variability, the initial serum plasma concentrations may fluctuate. [8] Concentrations below the recommended threshold for prophylaxis (< 700 µg/L) would be expected to be followed up. However, almost half of those patients had no further TDM episodes, and less than a third had their final concentrations ≥700 µg/L. Those patterns argue that a lack of consistency in concentration interpretation exists, with potential implications for patient safety from suboptimal prophylaxis such as IFIs, although no proven IFIs were recorded in our small sample. The inconsistency in TDM practice was further outlined by the fact that the majority of patients with concentrations ≥700 µg/L underwent further testing, with no rationale documented.
An area of concern was the low concentration levels for patients receiving the tablet formulation. The variable documentation of the timing of blood sampling, proton pump inhibitor use, and dietary intake limited the opportunity to evaluate the reason for these low concentrations. The decision-making diagram (Figure 2 ) and site-specific education have been designed to improve TDM practice and documentation.
Although there is a lack of literature on posaconazole TDM in regional settings, difficulties associated with laboratory result turnaround time have been highlighted. [13] Other non-reference centers may be using posaconazole without TDM, due to logistic barriers. Our study site is relatively close to the state reference center. Therefore, our findings would be expected at a greater scale for more remote centers.
The small number of patients is one of the study limitations. Outpatients (with a lower requirement for fast turnaround times) and patients transferred to another facility were excluded. The retrospective nature of this study often limited the information about circumstances surrounding TDM sampling and evaluation of low levels (i.e., trough or steady-state status, medication, or major nutritional changes), parameters that might have been known to the treating physicians but not necessarily documented in the notes. Results may have been considered less relevant due to the long turnaround times. Access to the results, which were not available online, required a phone call to the reference laboratory, risking a delay in appropriate actioning and increasing the time commitment of clinicians involved.
Unnecessary costs may be incurred due to inappropriate posaconazole TDM. This may be through both direct costs (for analysis, equipment, courier), and indirect costs (related to drawing the sample and time taken to follow up on results). Furthermore, patients may undergo redundant tests, increasing the risk of iatrogenic complications and causing unnecessary stress.
The findings from this study were presented to the managing hematologists of our hospital; the conclusions were discussed and optimal practices were agreed; a local protocol to optimize posaconazole TDM ordering and follow-up was designed as a result (Figure 2 ). Further research should be conducted to evaluate whether such protocols improve TDM practices in regional hospital settings.
Conclusion
Our results demonstrate an inconsistent approach to TDM ordering, interpretation, and subsequent actioning in a regional hospital setting. Evaluation of posaconazole use and TDM ordering in settings without TDM facilities should aim to identify challenges and particularities in each setting.
Incorporation of site-specific protocols can be developed to optimize use and concurrently maximize patient safety. concentration for prophylaxis in Australia [6] 
